General description
An orally active peptidyl hydroxamate-based broad-spectrum MMP inhibitor (IC50 in nM = 5, 6, 200, 20, 2, 1.8 and 3.8 for MMP-1, -2, -3, -7, -8, -14 and TACE, respectively) that targets both the substrate binding site and the active-site Zn2+. Marimastate is widely used in studying the involvement of MMPs in various cellular and pathological processes both in vitro and in vivo.
Packaging
Packaged under inert gas
Warning
Toxicity: Standard Handling (A)
Reconstitution
Following reconstitution, aliquot and freeze (-20°C). Stock solutions are stable for up to 6 months at -20°C.
Other Notes
Hansen, H.P., et al. 2002. Int. J. Cancer98, 210.
Tsuji, F., et al. 2002. Cytokine17, 294.
Barlaam, B., et al. 1999. J. Med. Chem.42, 4890.
Whittaker, M., et al. 1999. Chem. Rev.99, 2735.
Rasmussen, H.S., and McCann, P.P. 1997. Pharmacol. Ther.75, 69.
Legal Information
CALBIOCHEM is a registered trademark of Merck KGaA, Darmstadt, Germany
- UPC:
- 51441712
- Condition:
- New
- Weight:
- 1.00 Ounces
- HazmatClass:
- No
- WeightUOM:
- LB
- MPN:
- 444289-5MG